[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-356636-105":59,"doc-detail-356636-en":134},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":127,"head_meta":129,"extra_data":131,"updated_unix":133},105,"en","molecular-characteristics-and-prognosis-of-triple-negative-breast-cancer-stratified-by-her2-status","Molecular characteristics and prognosis of triple negative breast cancer stratified by HER2 status","","Background: HER2-low breast cancer is an emerging subtype, yet the molecular features and clinical outcomes of triple-negative breast cancer (TNBC) stratified by HER2 status remain insufficiently defined. Methods: Clinicopathological and genomic data from 1,006 TNBC patients were integrated from TCGA, METABRIC, and SRRSH cohorts, assessing survival, molecular alterations, and immune profiles by HER2 status. Results: TNBC classified as HER2-low showed lower histologic grade and Ki-67 in SRRSH but no significant survival differences. Genomics revealed distinct mutation patterns, and PIK3CA+MUC17 co-mutation related to worse survival. Conclusions: HER2 status influences clinicopathological, molecular, and immune features in TNBC, supporting translational refinement.",{"@graph":69,"@context":126},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/molecular-characteristics-and-prognosis-of-triple-negative-breast-cancer-stratified-by-her2-status/356636/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/molecular-characteristics-and-prognosis-of-triple-negative-breast-cancer-stratified-by-her2-status/356636.png","ImageObject",300,407,{"name":92,"@type":93},"Aria Callaghan","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-28","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118,122],{"name":109,"@type":110,"acceptedAnswer":111},"How were HER2 status groups defined in this TNBC study?","Question",{"text":112,"@type":113},"Patients were stratified by HER2 status into HER2-low and HER2-zero groups. HER2-low corresponded to lower HER2 expression, while HER2-zero represented absent expression as used in the study’s definition across cohorts.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What clinicopathological differences were found between HER2-low and HER2-zero TNBC?",{"text":117,"@type":113},"In the SRRSH cohort, HER2-low TNBC had a lower histological grade and Ki-67 index compared with the HER2-zero subgroup.",{"name":119,"@type":110,"acceptedAnswer":120},"Did HER2 status significantly affect survival outcomes in TNBC?",{"text":121,"@type":113},"No. The study reported no significant association between HER2 status and disease-free survival (DFS), recurrence-free survival (RFS), or overall survival (OS) in TNBCs.",{"name":123,"@type":110,"acceptedAnswer":124},"Which genomic and immune findings were linked to HER2 status?",{"text":125,"@type":113},"HER2-low TNBC showed higher mutated frequencies of PIK3CA, MUC17, and PTEN, while FAT3, RYR2, and CSMD3 were more frequently mutated in HER2-zero TNBC. Immune profiling indicated a higher percentage of plasma cells in patients with low HER2 expression.","https://schema.org",{"og:url":83,"og:type":128,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":130,"canonical":83},"index,follow",{"doc_id":132,"site_id":62},356636,1790784469,{"code":4,"msg":5,"data":135},{"doc_id":132,"user_id":136,"nickname":92,"user_avatar":137,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":138,"file_id":139,"file_url":140,"file_type":141,"file_size":142,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":44,"language":143,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":144,"faqs":145,"seo_title":146,"seo_description":67,"update_tm":147,"read_time":148,"preview_page_count":19,"preview_urls":149},962084926284,"https://ap-avatar.wpscdn.com/davatar_29158cc5080c5b710cf443261637dec0","Original Article  \nMolecular characteristics and prognosis of triple negative breast cancer stratified by HER2 status  \nXia Yang, Jin Wang, Huimin An, Yongtao He, Yi Gan, Qi Chen, Bo Liu, Wangyang Tang, Guoxiang Fu, Zhinong Jiang  \nDepartment of Pathology, Sir Run Run Shaw Hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang 310016, China.  \nAbstract  \nBackground: Human epidermal growth factor receptor 2 (HER2)-low breast cancer (BC) is an emerging subtype with specific clinicopathological features and therapeutic strategies. However, limited studies are available on the molecular characteristics and prognosis of triple-negative breast cancer (TNBC) .  \nMethods: This study was conducted using the clinicopathological and genomic data of 1006 TNBC patients, which were extracted from The Cancer Genome Atlas (TCGA), Molecular Taxonomy of Breast Cancer International Consortium (METABRIC), and Sir Run Run Shaw Hospital of Zhejiang University (SRRSH) cohorts. The clinicopathological features, survival outcomes, molecular characteristics, and immune profiles of TNBCs based on HER2 status were evaluated.  \nResults: Patients were stratified into HER2-low (N = 676) and HER2-zero (N = 330) groups according to their HER2 status. We found HER2-low TNBCs had a lower histological grade and Ki67 index compared to the HER2-zero subgroup in the SRRSH cohort. However, no significant association has been found between the HER2 status and the disease-free survival (DFS), recurrence-free survival (RFS), or overall survival (OS) in TNBCs. Genomic mutation analysis showed that the HER2-low TNBCs exhibited higher mutated frequencies of PIK3CA, MUC17, and PTEN, while FAT3, RYR2, and CSMD3 were more frequently mutated in the HER2-zero subgroup. Furthermore, the combined mutation of PIK3CA and MUC17, which had a higher frequency in the HER2-low subgroup, was associated with poorer survival in TNBCs. Immune profile analysis revealed a higher percentage of plasma cells in patients with low HER2 expression.  \nConclusion: Taken together, our study reflected the impact of the HER2 status on the clinicopathological and molecular features of TNBCs, which might offer additional introspection and improvement for translational studies and therapeutic decisions for TNBCs.  \nKeywords: Triple-negative breast cancer; Human epidermal growth factor receptor 2-low expression; Prognosis; Molecular characteristics; TCGA; METABRIC; HER-2  \nIntroduction  \nAccording to the American Society of Clinical Oncology (ASCO)/College of American Pathologists (CAP) 2018 recommendations,[1] human epidermal growth factor receptor 2 (HER2) status was stratified as HER2-negative and HER2-positive, which eliminated the definition of the HER2 equivocal status. The characterization of HER2 in breast cancer (BC) has dramatically improved in recent years. Currently, close attention has been paid to an emerging subtype of BCs: HER2-low BCs, which are defined as HER2 immunohistochemistry (IHC) 1+ or 2+ without ERBB2 gene amplification (fluorescence in situ hybridization [FISH]−) . [2] Almost half of the currently classified HER2-negative tumors are renamed as HER2-low. [2–5]  \nTriple-negative breast cancer (TNBC) is defined as the lack of estrogen receptor (ER) and progesterone receptor  \n\n| Access this article online |  |\n| --- | --- |\n| Quick Response Code: | Website:\u003Cbr>[www.cmj.org](www.cmj.org) |\n|  | DOI:\u003Cbr>10.1097/CM9.0000000000003942 |\n\n(PR) expression, and HER2 overexpression or amplification. [6,7] It is characterized by higher aggression and poorer prognosis than other BC subtypes and has limited therapeutic options. [7,8] In this BC subtype, HER2 status can range from the IHC score of absent to moderate with negative hybridization. However, little is known about the molecular characterization and prognosis value of HER2 status in TNBCs.  \nCurrently, Wang et al[9] found that the plasma SNORD33 signature can be used to predict the sensitivity of platinum-based chemothe","cbCaiai3xVfyp4Ge","https://ap.wps.com/l/cbCaiai3xVfyp4Ge","pdf",12538163,"English","# Abstract\n# Introduction\n# Methods\n## Study cohort and data acquisition","[{\"question\":\"How were HER2 status groups defined in this TNBC study?\",\"answer\":\"Patients were stratified by HER2 status into HER2-low and HER2-zero groups. HER2-low corresponded to lower HER2 expression, while HER2-zero represented absent expression as used in the study’s definition across cohorts.\"},{\"question\":\"What clinicopathological differences were found between HER2-low and HER2-zero TNBC?\",\"answer\":\"In the SRRSH cohort, HER2-low TNBC had a lower histological grade and Ki-67 index compared with the HER2-zero subgroup.\"},{\"question\":\"Did HER2 status significantly affect survival outcomes in TNBC?\",\"answer\":\"No. The study reported no significant association between HER2 status and disease-free survival (DFS), recurrence-free survival (RFS), or overall survival (OS) in TNBCs.\"},{\"question\":\"Which genomic and immune findings were linked to HER2 status?\",\"answer\":\"HER2-low TNBC showed higher mutated frequencies of PIK3CA, MUC17, and PTEN, while FAT3, RYR2, and CSMD3 were more frequently mutated in HER2-zero TNBC. Immune profiling indicated a higher percentage of plasma cells in patients with low HER2 expression.\"}]","Molecular characteristics and prognosis of triple negative breast cancer stratified by HER2 status | PDF",1790126521,23,[150,154,158,162],{"page_no":8,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d6df70e9fd7bde109a3edb64a9d652e6.webp",983,1324,{"page_no":14,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a2a7cb02fbeec9a63d305feaa8a39999.webp",982,1323,{"page_no":81,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e0541ac17a75ab43f47adeb2ee091e8e.webp",981,1321,{"page_no":19,"url":163,"width":164,"height":165},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8ded051070f21a47c89232afde619701.webp",980,1320]